Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Research & Development (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Research & Development for 12 consecutive years, with $9000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development fell 10.0% year-over-year to $9000.0, compared with a TTM value of $22000.0 through Sep 2025, up 107.41%, and an annual FY2024 reading of $53000.0, down 17.19% over the prior year.
  • Research & Development was $9000.0 for Q2 2025 at Arcadia Biosciences, down from $13000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.2 million in Q1 2021 and bottomed at -$337000.0 in Q4 2023.
  • Average Research & Development over 5 years is $324941.2, with a median of $255000.0 recorded in 2022.
  • The sharpest move saw Research & Development tumbled 167.4% in 2023, then surged 103.86% in 2024.
  • Year by year, Research & Development stood at $561000.0 in 2021, then decreased by 10.87% to $500000.0 in 2022, then crashed by 167.4% to -$337000.0 in 2023, then soared by 103.86% to $13000.0 in 2024, then crashed by 30.77% to $9000.0 in 2025.
  • Business Quant data shows Research & Development for RKDA at $9000.0 in Q2 2025, $13000.0 in Q4 2024, and $24000.0 in Q3 2024.